Cystathionine-β-synthase cDNA transfection alters the sensitivity and metabolism of 1-β-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: A model of leukemia in Down syndrome

Cancer Research

Volumn 60, Issue 22, 2000, Pages 6421-6426

  Taub, Jeffrey W ^a   Huang, Xi ^a   Ge, Yubin ^a   Dutcher, Julie A ^a   Stout, Mark L ^a   Mohammad, Ramzi M ^a   Ravindranath, Yaddanapudi ^a   Matherly, Larry H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHROMOSOME 21Q; CYTOTOXICITY; DNA TRANSFECTION; DOWN SYNDROME; DRUG ACTIVITY; DRUG METABOLISM; DRUG SENSITIVITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; LEUKEMIA CELL; PRIORITY JOURNAL; SURVIVAL RATE; TRANSCRIPTION REGULATION; TREATMENT OUTCOME;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CHROMOSOMES, HUMAN, PAIR 21; CYSTATHIONINE BETA-SYNTHASE; CYTARABINE; DEOXYCYTIDINE KINASE; DNA, COMPLEMENTARY; DOWN SYNDROME; FEMALE; GENE EXPRESSION; HUMANS; LEUKEMIA, EXPERIMENTAL; MALE; MICE; MICE, INBRED ICR; MICE, SCID; TRANSFECTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0033677393     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Down's syndrome and leukemia: Epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis
2. Down syndrome and leukemia
3. Down syndrome and leukemia: Unusual clinical aspects and unexpected methotrexate sensitivity
4. Excessive chemotherapy-related myelotoxicity in children with Down syndrome and acute lymphoblastic leukaemia
5. Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemia
6. Clinical characteristics and treatment outcome of children with acute lymphocytic leukemia and Down, s syndrome and acute lymphocytic leukemia. A Pediatric Oncology Group study
7. In vivo folic acid supplementation partially corrects in vitro methotrexate toxicity in patients with Down syndrome
8. Acute myeloid leukemia (AML) in Down's syndrome is highly responsive to chemotherapy: Experience on Pediatric Oncology Group AML study 8498
9. Acute myelogenous leukemia in Down's syndrome: Report of a single pediatric institution using a BFM treatment strategy
10. Distinctive demography, biology, and outcome of acute myeloid leukemia and myetodysplastic syndrome in children with Down syndrome: Children's Cancer Group Studies 2861 and 2891
11. Down's syndrome (DS) and acute myelogenous leukemia (AML). A population based study in the five Nordic countries
12. Favorable treatment outcome in children with acute myeloid leukemia and Down syndrome
13. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome
14. Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM study group
15. Cancer statistics, 1998
16. Enhanced metabolism of 1-β-D-arabinofuranosylcytosine in Down syndrome cells: A contributing factor to the superior event free survival of Down syndrome children with acute myeloid leukemia
17. Myeloblasts from Down syndrome children with acute myeloid leukemia have increased in vitro sensitivity to 1-β-D-arabinofuranosylcytosine and daunorubicin
18. Expression of chromosome 21-localized genes in acute myeloid leukemia: Differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to 1-β-D-arabinofuranosylcytosine and daunorubicin
19. Disorders of transsulfuration
20. Methotrexate sensitivity in Down's syndrome: A hypothesis
21. The metabolic basis for conthination chemotherapy
22. Biochemical interactions between methotrexate and 1-β-D-arabinofuranosylcytosine in hematopoietic cells of children: A Pediatric Oncology Group study
23. A yeast system for expression of human cystathionine β-synthase: Structural and functional conservation of the human and yeast genes
24. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
25. Cystathionine β-synthase (Human)
26. Propagation of Waldenstrom's macroglobulinemia cells in vitro and in severe combined immune deficient mice: Utility as a preclinical drug screening model
27. Establishment of a human B-CLL xenograft model: Utility as a preclinical therapeutic model
28. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands
29. 1-β-D-arabinofuranosylcytosine transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma
30. Treatment of childhood acute myeloid leukaemia
31. Reduced folate carrier gene expression in childhood acute lymphoblasric leukemia: Relationship to immunophenotype and ploidy
32. Does Down syndrome support homocysteine theory of arteriosclerosis?
33. Is absence of atheroma in Down syndrome due to decreased homocysteine levels?
34. Methylation des phospholipides dans les fibroblasles de patients atteints de trisomie 21
35. Slowed synthesis of DNA and methionine is a pathogenetic mechanism common to dementia in Down's Syndrome, AIDS and Alzheimer's disease?
36. Selective variegated methylation of the p15 CpG island in acute myeloid leukemia
37. Analysis of DNA methylation of the 5' region of the deoxycytidine kinase gene in CCRF-CEM-sensitive and cladribine (CdA)- and 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (CAFdA)-resistant cells
38. Human deoxycyridine kinase is located in the nucleus
39. The intracellular localization of deoxycytidine kinase
40. Deoxycytidine kinase is phosphorylated in vitro by protein kinase Cα
41. Functional compartmentation of dCTP pools. Preferential utilization of salvaged deoxycytidine for DNA repair in human lymphoblasts
42. Gene therapy strategies for leukemia
43. Immunotherapy in acute myelogenous leukemia and myelodysplastic syndrome
44. Gene delivery system targeted to JL1 antigen of leukemia T cells
45. HER2-targeted gene transfer